AGIO - Agios Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$42.33
DETAILS
HIGH:
$54.00
LOW:
$32.00
MEDIAN:
$41.00
CONSENSUS:
$42.33
DOWNSIDE:
1.08%
About Agios Pharmaceuticals, Inc. (https://www.agios.com)
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brian Goff | Chief Executive Officer & Director | 1969 | $1,451,457 USD |
| Krishnan Viswanadhan | Chief Strategy & Operations Officer | 1979 | $931,509 USD |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 1980 | $887,232 USD |
| Cecilia Jones | Chief Financial Officer | 1975 | $791,835 USD |
| James William Burns | Chief Legal Officer | 1978 | $780,510 USD |
| Craig Thompson | Co-Founder | 1953 | $50,000 USD |
| Lewis Clayton Cantley | Co-Founder | 1949 | $50,000 USD |
| Shin-San Su | Co-Founder | 1956 | $50,000 USD |
| Tak Wah Mak FRSC | Co-Founder | 1946 | $50,000 USD |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer | 1982 | – |